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Ex situ dual hypothermic oxygenated machine perfusion (DHOPE) and normothermic 
machine perfusion (NMP) of donor livers may have a complementary effect when 
applied sequentially. While DHOPE resuscitates the mitochondria and increases he-
patic adenosine triphosphate (ATP) content, NMP enables hepatobiliary viability as-
sessment prior to transplantation. In contrast to DHOPE, NMP requires a perfusion 
solution with an oxygen carrier, for which red blood cells (RBC) have been used in 
most series. RBC, however, have limitations and cannot be used cold. We, therefore, 
established a protocol of sequential DHOPE, controlled oxygenated rewarming 
(COR), and NMP using a new hemoglobin-based oxygen carrier (HBOC)-based perfu-
sion fluid (DHOPE-COR-NMP trial, NTR5972). Seven livers from donation after circu-
latory death (DCD) donors, which were initially declined for transplantation 
nationwide, underwent DHOPE-COR-NMP. Livers were considered transplantable if 
perfusate pH and lactate normalized, bile production was ≥10 mL and biliary 
pH > 7.45 within 150 minutes of NMP. Based on these criteria five livers were trans-
planted. The primary endpoint, 3-month graft survival, was a 100%. In conclusion, 
sequential DHOPE-COR-NMP using an HBOC-based perfusion fluid offers a novel 
method of liver machine perfusion for combined resuscitation and viability testing of 
suboptimal livers prior to transplantation.
K E Y W O R D S
clinical research/practice, donors and donation: extended criteria, ischemia reperfusion injury 
(IRI), liver allograft function/dysfunction, liver transplantation/hepatology, organ perfusion 
and preservation, organ procurement, organ procurement and allocation
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1  | INTRODUC TION
Ex situ machine perfusion is increasingly investigated as a tool to in-
crease the number of donor livers for transplantation and to reduce 
posttransplant complications. Machine perfusion, was recently intro-
duced in clinical practice using two different temperature protocols: 
hypothermic (4-12°C) or normothermic (37°C) machine perfusion.1-5 
(Dual) hypothermic oxygenated perfusion ([D]HOPE) can be applied 
to resuscitate the mitochondria and increase hepatic adenosine tri-
phosphate (ATP) content, resulting in less cell injury, including less 
choliangiocyte injury. Normothermic machine perfusion (NMP) al-
lows for ex situ functional testing of (extended criteria) donor livers 
prior to transplantation and suboptimal donor livers have been suc-
cessfully transplanted after NMP.2,6-8 (D)HOPE and NMP may there-
fore have a complementary effect when applied sequentially.9,10 In 
preclinical studies using human donor livers, it was previously shown 
that a short period of DHOPE prior to NMP results in increased 
ATP concentrations, less hepatobiliary injury and improved function 
during the NMP phase, compared to direct end-ischemic NMP.9,10
Different perfusion solutions have been used for (D)HOPE and 
NMP. A perfusion fluid based on human red blood cells (RBC) is 
frequently used for NMP.11-13 The use of RBC, however, has sev-
eral drawbacks. Firstly, RBC are a relatively scarce human blood 
product.14 Secondly, RBC may induce an immune reaction or cause 
an infection.14,15 Lastly, RBC cannot be used during (D)HOPE due 
to increased stiffness of the erythrocyte lipid membranes and he-
molysis at low temperatures. These drawbacks press the need for 
an alternative oxygen carrier, especially when hypothermic and 
normothermic machine perfusion are combined. Hemoglobin-based 
oxygen carriers (HBOC) are a suitable alternative for the use of RBC 
in ex situ liver machine perfusion. The bovine derived HBOC-201 
(Hemopure) has previously been used successfully in experimental 
and preclinical studies of liver machine perfusion.14,16,17
Based on the presumed complementary effect of (D)HOPE and 
NMP we have combined these two techniques in a clinical machine 
perfusion protocol using an HBOC-201-based solution. The use of 
this perfusion solution eliminates the need to change the perfusion 
fluid during different temperature phases. Donor livers that were 
initially declined for transplantation nationwide were subjected to 
a combined protocol of DHOPE, controlled oxygenated rewarming 
(COR), and subsequent viability testing during NMP (DHOPE-COR-
NMP Trial). This report describes the first transplantations of ini-
tially nation-wide declined livers that underwent ex situ machine 
perfusion with the HBOC-201-based perfusion fluid.
2  | MATERIAL S AND METHODS
2.1 | Study protocol
Between August 2017 and April 2018, 20 livers were offered for 
inclusion in the DHOPE-COR-NMP study. All livers were declined 
for regular transplantation by the three liver transplant centers in 
the Netherlands. Thirteen livers were secondarily declined because 
of logistical reasons, long agonal phase (in case of donation after 
circulatory death), or macroscopic fibrosis/cirrhosis (Figure 1 and 
Figure S1). Seven livers were accepted to undergo DHOPE-COR-
NMP. All seven livers were initially declined for transplantation be-
cause of a combination of risk factors, as described in Table 1. The 
median donor risk index was 2.82 (IQR 2.52-2.97), reflecting the sub-
optimal quality of these livers.
The study protocol was approved by the medical ethical review 
committee of our center (METc2016.281) and published in the na-
tional registry of clinical trials (www.trialregister.nl; NTR5972). The 
primary outcome parameter was 3-month graft survival. All recipi-
ents gave written informed consent.
2.2 | Procurement of donor livers
All donor livers were procured in a standard manner by a dedi-
cated procurement team. After withdrawal of mechanical support, 
F I G U R E  1   Flow chart of livers offered 
in the context of the DHOPE-COR-NMP 
Trial. After initial decline by all Dutch 
liver transplant centers a total number 
of 20 livers were offered for inclusion 
in this trial. Thirteen livers did not 
undergo machine perfusion due to 
logistical reasons, long agonal phase, 
or macroscopic findings. Seven livers 
underwent machine perfusion for 
resuscitation and viability assessment. 
DHOPE, dual hypothermic oxygenated 
machine perfusion; COR, controlled 
oxygenated rewarming; NMP, 
normothermic machine perfusion [Color 
figure can be viewed at wileyonlinelibrary.
com]
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circulatory death was awaited, followed by a mandatory 5 minutes 
“no touch” period before procurement surgery was started. Cold in 
situ flush was performed with UW cold storage solution with the ad-
dition of 50 000 IU of heparin. After procurement, the livers were 
transported to our center using static cold storage. Upon arrival, the 
livers were prepared for machine perfusion, as described previously.11
2.3 | Machine perfusion settings
A combined machine perfusion protocol of 1 hour of DHOPE (re-
suscitation phase), 1 hour of COR, and subsequent NMP (viability 
testing phase) was established (Figure 2). For machine perfusion at 
different temperatures the Liver Assist (Organ Assist, Groningen, 
the Netherlands) perfusion device was used. DHOPE was performed 
at 10°C. During COR the temperature was gradually increased about 
1°C per 2 minutes, to 37°C at the start of NMP. Portal vein and he-
patic artery pressures were set at 5 and 11 mm Hg during DHOPE, 
and gradually increased during COR to 11 and 70 mm Hg at the start 
of NMP, respectively.
During DHOPE, the perfusion fluid was oxygenated with 1 L/
min 100% O2, resulting in a perfusate pO2 > 80 kPa, as described 
previously.2 During NMP an air/oxygen mixture was used aimed to 
reach an arterial perfusate pO2 of 10.0-13.3 kPa and a venous ox-
ygen saturation of 55% to 75%. To obtain these targets, FiO2 was 
varied between 21% and 40%.
Arterial perfusate samples were collected every half hour and 
analyzed using the ABL 90 Flex analyzer (Radiometer, Brønhøj, 
Denmark). In addition, venous perfusate samples were collected and 
analyzed every hour, to determine oxygen consumption. Oxygen 
consumption was calculated based on the difference between 
arterial and venous oxygen content. The following equation was 
used, ([{ApO2−VpO2} × K /760] × total flow) + ([{AsO2−VsO2} × Hb × 
c × 0.0001 ] × total flow) / Liver weight × 100.18 Where pO2 was in 
mm Hg, sO2 in %, Hb in g/dL, total flow (sum of arterial and portal 
flow) in mL/min and liver weight in g. K was a constant (0.0225) and 
c the oxygen binding capacity of HBOC (1.26).
Bile was collected from COR-NMP onwards and its quantity mea-
sured. Additionally, every half hour bile was collected under mineral oil 
to determine biliary pH and HCO3-, as described previously.8,19 Mineral 
oil prevented exposure of bile to ambient air, thus preventing the ex-
change of CO2 molecules, which influences biliary pH via HCO3-.
2.4 | Perfusion fluid
To facilitate perfusion at different temperatures, an acellular perfu-
sion solution based on a bovine-derived HBOC (HBOC-201, HBO2 
Therapeutics, Souderton, PA) was used. In addition to HBOC-201, 
the perfusion fluid contained gelofusine, albumin, metronidazole, ce-
fazolin, nutrients, glutathione, insulin, heparin, and NaHCO3. Details 
of the perfusion solution composition are provided in Table S1. As 
of liver #6, taurocholate was added to the perfusion fluid (50 mg at 
baseline), followed by a continuous infusion of 7.7 mg/h during the 
NMP phase.20 Taurocholate was produced according to GMP by our 
hospital pharmacy.
2.5 | Viability testing—assessment of 
hepatobiliary function
Liver viability and function were assessed during the NMP phase 
using predefined viability criteria, including sufficient bile production 
TA B L E  1   Donor characteristics of livers that were accepted to undergo machine perfusion
Liver 1 Liver 2 Liver 3 Liver 4 Liver 5 Liver 6 Liver 7
Age (y) 42 63 47 52 46 62 63
DBD/DCD donor DCD DCD DCD DCD DCD DCD DCD
BMI / degree of 
steatosis
BMI 21 BMI 28 BMI 33, 
Histologically 
>60% steatosis




Peak AST 1676 U/L, 
peak ALT 1375 U/L, 
peak γGT 166 U/L
– – Peak γGT 
340 U/L
Peak AST 161 U/L, 
peak ALT 270 U/L, 
peak γGT 254 U/L
Peak AST 201 U/L, 
peak ALT 175 U/L
–





dWIT (min)a 29 23 30 33 27 35 25
CIT (min)b 289 306 525 294 256 278 221
Donor hepatectomy 
time (min)c
59 82 96 28 11 44 36
DRI30 2.53 2.82 2.46 2.92 2.50 3.75 3.03
ET-DRI31 2.65 2.92 2.47 3.31 2.85 2.88 2.87
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body-mass index; CIT, cold ischemia time; DBD, donation after brain death; DCD, 
donation after circulatory death; DRI, donor risk index; dWIT, donor warm ischemia time; ET-DRI, Eurotransplant donor risk index; γGT, 
γ-glutamyltransferase.
adWIT is defined as the time from withdrawal of mechanical support until the start of in situ cold perfusion. 
bCIT is defined as the time from in situ cold perfusion until the start of machine perfusion. 
cDonor hepatectomy time is defined as the time from in situ cold perfusion until the time of hepatectomy. 
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with a biliary pH of >7.45, and normalization of perfusate pH and lac-
tate (Table 2).5,7,8,21,22 The liver was considered acceptable for trans-
plantation, if all criteria were met within the first 150 min of NMP. 
If the liver did not meet the predefined viability criteria, machine 
perfusion was terminated. If the liver did meet the predefined viabil-
ity criteria, machine perfusion was continued and the recipient was 
brought to the operating room. When the hepatectomy of the native 
liver was almost complete, machine perfusion was terminated and 
the donor liver flushed out with 2 L of cold UW cold storage solution 
to remove the HBOC-based machine perfusion fluid. As routinely 
performed in our center, the first 400 mL of venous blood from the 
liver was drained and discarded to avoid spill of UW Cold Storage 
Solution into the recipient circulation.
3  | RESULTS
3.1 | Machine perfusion characteristics
Five of the seven livers (liver #1, and #4-#7) that underwent 
DHOPE-COR-NMP were identified as transplantable based on 
functional assessment during NMP (Table 3). Median cold isch-
emia time of all livers was 289 minutes (IQR 256-306 minutes). 
Machine perfusion times per liver are provided in Table 4. Median 
total duration of machine perfusion was shorter for the non-
transplanted livers due to termination of machine perfusion after 
these livers did not meet all predefined viability criteria within 
150 min of NMP.
Both portal vein and hepatic artery flow remained low during 
DHOPE and increased during COR. At 150 minutes of NMP, me-
dian portal vein flow was 1680 mL/min (IQR 1460-1740 mL/min) 
(Figure 3A). Overall, resistance in the portal vein decreased to-
wards NMP, but remained relatively high in liver #3 (Figure 3B). At 
150 minutes of NMP, median hepatic artery flow was 547 mL/min 
(IQR 240-737 mL/min). Furthermore, hepatic artery flow was vari-
able between the livers (Figure 3C). Resistance in the hepatic artery, 
generally remained <0.2 mm Hg*min/L/g, except for resistance in 
liver #7 (Figure 3D). During COR, total flow increased as well, to a 
median of 2512 min (IQR 2133-2570 min) at 150 minutes of NMP 
(Figure 3E).
3.2 | Hepatobiliary function and damage during 
machine perfusion
Perfusate pH normalized within 150 minutes of NMP of liver #1, #2, 
and #4 to #7, but not in liver #3, despite the addition of 25 mL 8.4% 
NaHCO3 (Figure 4A). Perfusate lactate normalized within 150 min-
utes of NMP in all livers, except for liver #3 (Figure 4B). Furthermore, 
all livers produced sufficient amounts of bile. Bile production of 
liver #6 appeared lower, however, this was caused by a cannula-
tion problem of the bile duct (Figure 4C). Alanine aminotransferase 
(ALT) concentrations in perfusate of the transplanted livers were 
<2000 U/L. In the two non-transplanted livers ALT concentrations 
were >2000 U/L, with a peak ALT concentration of 8460 U/L in 
liver #3 (Figure 4D). Livers #1 and #4 to #7 produced bile with a 
F I G U R E  2   Overview of the machine 
perfusion protocol. A, The machine 
perfusion protocol included 1 h of 
DHOPE, 1 h of COR, and subsequent 
NMP for at least 150 minutes. Each phase 
of machine perfusion served a different 
purpose as described in the upper part 
of the figure. Machine perfusion settings 
were adjusted according to the perfusion 
temperature. The temperature was kept 
at 10°C during DHOPE and was gradually 
increased to 37°C during the COR phase, 
after which the liver was functionally 
tested during NMP. PV and mean HA 
pressure were set at 5 and 25 mm Hg, 
respectively, during DHOPE and were 
gradually increased during COR to 10 
and 70 mm Hg, respectively, at the start 
of NMP. DHOPE, dual hypothermic 
oxygenated machine perfusion; COR, 
controlled oxygenated rewarming; HA, 
hepatic artery; NMP, normothermic 
machine perfusion; PV, portal vein [Color 
figure can be viewed at wileyonlinelibrary.
com]
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F I G U R E  3   Flows and resistance during machine perfusion. A, PV flows were low during DHOPE. After 150 min of NMP, median portal 
vein flow was 1680 mL/min (IQR 1460-1740 mL/min). B, Resistance in the portal vein was low, except for liver #3. C, Hepatic artery (HA) 
flows were low during DHOPE and COR. During NMP hepatic artery flows varied between 100 and 900 mL/min. At 150 min of NMP, 
median hepatic artery flow was 547 mL/min (IQR 240-737 mL/min). D, Resistance in the hepatic artery was <0.2 mm Hg*min/L/g, except 
for liver #7. E, Total flow increased to a median of 2512 min (IQR 2133-2570 min) at 150 minutes of NMP. The red lines represent the non-
transplanted livers and the green lines represent the transplanted livers. DHOPE, dual hypothermic oxygenated machine perfusion; COR, 
controlled oxygenated rewarming; HA, hepatic artery; IQR, interquartile range; NMP, normothermic machine perfusion; PV, portal vein; Tx, 
transplantation [Color figure can be viewed at wileyonlinelibrary.com]
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pH > 7.45, whereas livers #2 and #3 did not (Figure 4E). Bile duct 
biopsies of these two livers revealed signs of substantial histological 
injury (Figure S2).
Median oxygen consumption was 0.14 mL O2/min/100 g liver 
weight during DHOPE and increased during COR to a median peak 
value of 2.77 mL O2/min/100 g liver weight during NMP.
3.3 | Pre‐ and postoperative outcomes
Median follow up after transplantation was 197 days (IQR 
152-307 days). Laboratory values of the recipients are shown in 
Figure 6. Serum ALT levels rapidly decreased during the first week 
after transplantation and values were (nearly) normal at 30 and 
90 days after transplantation. The recipients of liver #1 and #7 
had remarkably low peak serum ALT concentrations of 201 and 
337 U/L, respectively (Figure 5A). Serum total bilirubin levels rap-
idly decreased during the first postoperative days in all recipients. 
However, a temporary peak in serum bilirubin was noted at the end 
of the first week in recipients of liver #4 and #6 (Figure 5B). None 
of the transplanted livers classified for early allograft dysfunction.23
Thus far we have observed a 100% patient and graft survival. 
None of the recipients has developed clinically evident non-anas-
tomotic strictures of the biliary tree during the median follow-up of 
197 days (6.5 months).
4  | DISCUSSION
The clinical series described in this report provides two novel 
findings that are relevant for the further development of machine 
perfusion technology in organ transplantation. First, we have 
successfully used a combination of hypothermic and normother-
mic machine perfusion to resuscitate and select initially declined 
suboptimal livers for transplantation. The 100% graft survival at 
3 months, which was the primary end point, indicated the safety 
and feasibility of the procedure. Secondly, we have shown that 
an HBOC-based machine perfusion solution can be safely used in 
clinical liver transplantation.
Several groups have described the successful use of NMP to se-
lect suboptimal and initially declined donor livers.7,12 Although the 
optimal parameters for viability assessment are still under debate, 
most groups have been using a combination of bile production, per-
fusate lactate levels, and pH as markers of hepatocellular function. 
We have previously suggested to use biliary pH and bicarbonate as 
markers of biliary epithelial (cholangiocellular) viability.22 Biliary epi-
thelium actively modifies bile composition by the secretion of bicar-
bonate, resulting in an alkalotic biliary environment. This alkalotic 
environment protects biliary epithelial cells against the detergent 
effects of hydrophobic bile salts, a phenomenon known as the “bi-
carbonate umbrella.”24 In a clinical series of liver NMP, Watson et al 
have recently confirmed the potential usefulness of biliary pH as 
marker of biliary viability.12 We have, therefore, added biliary pH as 
a bile duct viability criterion to our protocol. Of the four predefined 
selection criteria, the criterion for biliary pH was the most frequent 
reason for secondary discard in these clinical series.
Although, favorable outcomes after NMP regarding graft and pa-
tient survival have been reported, it has not yet been demonstrated 
that NMP protects the cholangiocyte compartment.7,12,25 (D)HOPE 
in DCD liver grafts has, on the other hand, been described to reduce 
histological signs of biliary ischemia-reperfusion injury and the inci-
dence of posttransplant cholangiopathy.2,3,26 Furthermore, DHOPE 
has been shown to reduce ischemia reperfusion injury via resusci-
tation of the mitochondria and the increase in hepatic ATP content, 
thereby also protecting the hepatocytes.2,3,6 The latter might ex-
plain why postoperative peak ALT was lower in our recipients than 
in the studies that compared SCS to end-ischemic NMP alone.7,12 
However, definitive conclusions on this topic cannot be drawn from 
the current study due to the lack of a control group.
In this study we combined the presumed benefits of DHOPE 
and NMP to resuscitate and select high-risk donor livers that can 
be safely transplanted, despite initial nationwide decline. Besides 
a 100% graft survival at a median follow up of 197 days, none of 
the recipients has developed clinical signs of posttransplant chol-
angiopathy so far. The development of posttransplant cholangiop-
athy was, however, not the primary outcome of this study and was 
based on clinical symptoms and laboratory findings, rather than on 
imaging studies. Therefore, subclinical cases of cholangiopathy may 
have been missed and final conclusions on the efficacy of combined 
DHOPE, COR, and NMP in the prevention of posttransplant cholan-
giopathy require longer follow-up in a larger series.
We applied sequential DHOPE and NMP linked by a controlled re-
warming phase, as sudden temperature shifts may contribute to cellu-
lar injury.27,28 A previous clinical study has indicated that a short period 
of COR prior to implantation of donor livers results in less hepatocellu-
lar injury, compared to direct implantation of a cold stored donor liver, 
as evidenced by lower postoperative peak transaminases and a higher 
graft survival rate at 6 months after transplantation.28 Based on the 
relative small number of livers included in the current study and the ab-
sence of a control group, we cannot draw conclusions on the value of 
the COR phase. Previous preclinical studies have shown that (D)HOPE 
and NMP can also be combined without a COR phase.9,10
TA B L E  2   Viability criteria for donor liver assessment during 
NMP phase
Viability criteria
• Cumulative bile production of ≥10 mL at 150 min of NMP and 
≥4 mL in the preceding hour.8
• Lactate concentration in perfusate is within “normal” values 
(0.5-1.7 mmol/L) within 150 min of NMP.5,7
• Perfusion fluid pH is within normal values (7.35-7.45) within 
150 min of NMP, without the need for repeated addition of 
NaHCO3.5,7• Biliary pH of >7.45 within 150 min of NMP.21,22
All predefined viability criteria had to be met in order to consider a liver 
transplantable.
NMP, normothermic machine perfusion.
1208  |     DE VRIES Et al.
For the application of this combined machine perfusion protocol 
we have developed a perfusion fluid that can be used at various tem-
peratures and eliminates the use of a third party human blood prod-
uct. While during hypothermic machine perfusion, oxygen can be 
dissolved in the perfusion solution, during NMP an oxygen carrier is 
necessary. Perfusion solutions based on RBC, which are mostly used 
for NMP, cannot be used at low temperatures due to increasing lipid 
membrane stiffness and the risk of hemolysis. In contrast to RBC, 
HBOC can be used at low temperatures. In addition, HBOC-201, 
used in this study, has a lower oxygen affinity than human Hb in 
erythrocytes and thus gives off the oxygen more easily. In the cold, 
the affinity of HBOC-201 for oxygen increases, similar to that of 
human Hb in erythrocytes, but is still less.
HBOC-201 has previously been used in experimental and pre-
clinical studies on ex-situ liver machine perfusion, but not in clinical 
practice.14,16,17 In a study with discarded human livers, NMP with 
an HBOC-201-based perfusion fluid resulted in similar outcome 
compared to NMP with RBC, indicating HBOC-201 as a suitable al-
ternative for RBC.14 Our group reported higher ATP concentration, 
and cumulative bile production in discarded human livers undergo-
ing NMP with an HBOC-201-based solution, compared to perfusion 
with an RBC-based perfusion fluid.16 Altogether these preclinical 
studies and the currently presented first, clinical application indicate 
that HBOC-201 can be used as a substitute for RBC in fluids for ma-
chine perfusion of donor organs.
A limitation of this series is a lack of a control group. However, 
livers of suboptimal quality with a perceived high risk of primary non-
function or early allograft dysfunction were included in the current 
study, making it unethical, in our opinion, to transplant these livers 
without resuscitation and functional assessment. Furthermore, this 
study cannot discriminate between the beneficial effects of DHOPE, 
COR, and NMP separately. Finally, extrahepatic bile duct biopsies 
of the two livers that were secondary declined for transplantation, 
based on their failure to produce bile with a pH > 7.45 during NMP, 
were taken. Yet, biopsies of higher level bile ducts were not taken. 
Although we have previously shown that the degree of histological 
injury of the extrahepatic bile duct of a donor liver after cold stor-
age is representative for the degree of injury of the proximal biliary 
tree, including larger intrahepatic ducts,29 we do not formally know 
whether this is also true after NMP.
A potential limitation of HBOC is its susceptibility to a conver-
sion into methemoglobin, especially in the venous phase with low 
oxygen saturation. In contrast to erythrocytes, HBOC do not con-
tain NADH-dependent enzyme methemoglobin reductase, which is 
responsible for converting methemoglobin back to hemoglobin. We 
have noted a gradual increase in methemoglobin during NMP, but 
not during DHOPE when the perfusion fluid was oxygenated with an 
FiO2 of 100% (Figure S3). In a separate experiment, we have noted 
that the percentage of methemoglobin can be corrected or slowed 
down by the addition of extra HBOC-201, glutathione, or vitamin 
C to the perfusion fluid (Figure S3). However, we do not prefer the 
use of vitamin C due to its effects on the pH and osmolality of the 
perfusion fluid.
In conclusion, this first clinical experience demonstrates the 
feasibility of combined hypo- and normothermic machine perfusion 
after traditional static cold storage of suboptimal liver grafts. The 
combination of oxygenated hypothermic and normothermic perfu-
sion protects livers against ischemia-reperfusion injury and enables 
hepatobiliary viability assessment prior to transplantation. The use 
of a novel HBOC-201-based perfusion fluid eliminated the need to 
TA B L E  3   Viability criteria overview and transplantation decision per liver
Liver #1 Liver #2 Liver #3 Liver #4 Liver #5 Liver #6 Liver #7
Perfusate pH + + − + + + +
Perfusate latate + + − + + + +
Bile production + + + + + + +
Biliary pH + − − + + + +
Transplantation (yes/no) Yes No No Yes Yes Yes Yes
+, the liver met this viability criterion; −, the liver did not meet this viability criterion.
TA B L E  4   Machine perfusion times per liver
Liver #1 Liver #2 Liver #3 Liver #4 Liver #5 Liver #6 Liver #7
Total duration of NMP 
(min)
347 163 180 397 301 373 391
Duration of NMP from 
viability assessment 
onwards (min)
197 – – 247 157 223 241
Total machine perfusion 
time (DHOPE-COR-NMP) 
(min)
467 283 300 517 421 493 511
DHOPE, dual hypothermic oxygenated machine perfusion; COR, controlled oxygenated rewarming; NMP, normothermic machine perfusion.
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F I G U R E  4   Machine perfusion fluid biochemistry. A-B, Biochemical parameters used for viability assessment of the liver. In all but one 
liver, perfusate pH and lactate values normalized within 150 minutes after start of the NMP. C, All livers produced sufficient amounts of 
bile. Liver #6 seemingly produced less bile due to a cannulation problem of the bile duct. D, ALT perfusate levels were <2000 U/L in the 
transplanted livers and >2000 U/L in the nontransplanted livers. E, Biliary pH, a marker of biliary epithelial viability, increased to >7.45 in all 
livers that were transplanted, whereas biliary pH remained <7.45 in the livers that were not transplanted livers. The red lines represent the 
nontransplanted livers and the green lines represent the transplanted livers. ALT, alanine aminotransferase; NMP, normothermic machine 
perfusion [Color figure can be viewed at wileyonlinelibrary.com]
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change perfusion fluid during various temperature phases and ap-
peared to be a safe alternative for RBC as oxygen carrier in ex situ 
donor organ machine perfusion. This new protocol of ex situ ma-
chine perfusion provides a tool to safely expand the pool of organs 
for liver transplantation.
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